Moreover, bi- and tri-specific killer-cell engagers (BiKEs and TriKEs), also referred to as NK cell engagers (NKCEs), have been recently introduced to link NK cell receptors with tumor-presenting antigens, thus bringing NK cells and tumors into proximity and offering a cost-effective solution for NK-cell-based therapies [29]. This evidence concerns the gene KLRD1 and neoplasm.